Merck & Co. is no longer in talks to acquire biotech firm Revolution Medicines Inc. after the two companies couldn’t agree on ...

Merck & Company Inc (NYSE:MRK) has ceased discussions to acquire biotechnology firm Revolution Medicines Inc (NASDAQ:RVMD), following a failure to reach an agreement on the company’s valuation.

The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...

Revolution Medicines shares drop after Merck buyout talks collapse over price. Deal was valued at $28-32B before negotiations ...

Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck ...

It doesn't look like the company will end up in the arms of an acquirer soon, after all.

Revolution Medicines shares tumbled in premarket trading Monday after The Wall Street Journal reported that drugmaker Merck is no longer in talks to buy the cancer-drug biotech. Shares of Revolution, ...

The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.

Revolution Medicines (RVMD) stock jumped 5% after a report that Merck (MRK) is in talks to buy the cancer drugmaker.

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in what would be the latest big deal in the red-hot ...

Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...

The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at ...